Table 2.

Antiproliferative activity of PRN1371 across cancer cell lines

Cell lineTumor typeFGFR pathway alterationPRN1371 IC50 (nmol/L) ± SDMaximum inhibition (%)
RT4Bladder, transitional cell carcinomaFGFR3:TACC3 fusion4.0 ± 1.756.1
RT112Bladder, transitional cell carcinomaFGFR3:TACC3 fusion4.1 ± 1.484.4
ANC3AEndometrial adenocarcinomaFGFR2-N549K mutation43.3 ± 4.083.6
L17Hepatocellular carcinomaFGF19 amplification33.1 ± 9.191.7
SNU878Hepatocellular carcinomaFGF19 amplification120 ± 698.5
JHH7Hepatocellular carcinomaFGF19 amplification231 ± 4080.5
Hep3BHepatocellular carcinomaFGF19 amplification6.0 ± 4.993.8
NCI-H716Colorectal adenocarcinomaFGFR2 amplification/C3 truncation and FGFR2:COL14A1 fusion2.0 ± 1.798.0
SNU16Gastric carcinomaFGFR2 amplification/C3 truncation2.6 ± 2.288.5
OPM2Multiple myelomaFGFR3 translocation (t4;14) and FGFR3-K562E mutation14.0 ± 0.195.5
HCT116Colon carcinomaWild-type4,819 ± 1,85877.8